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Backgrounds/Aims: Backgrounds/Aims: In Korea, hepatocellular carcinoma (HCC) is the sixth 
most common cancer and results in the second-highest cancer death rate among all cancers. 
We aimed to describe the characteristics of patients who were newly diagnosed with HCC in 
Korea between 2008 and 2011.
Methods: The Korean Primary Liver Cancer Registry (KPLCR) is a random sample consisting 
of approximately 15% of patients with newly diagnosed primary liver cancer registered in 
the Korean Central Cancer Registry. We investigated the baseline characteristics, treatment 
modalities, and overall survival (OS) of patients with HCC registered in the KPLCR between 
2008 and 2011.
Results: A total of 6,083 patients were histologically or radiologically diagnosed with HCC. 
The hepatitis B virus was the predominant HCC etiology (72.0%). According to the Barcelona 
Clinic Liver Cancer (BCLC) staging system, stages 0, A, B, C, and D accounted for 8.6%, 39.7%, 
11.5%, 33.8%, and 6.9%, respectively. Transarterial therapy (41.7%) was the most commonly 
performed initial treatment, followed by best supportive care (21.7%), surgical resection 
(16.7%), and local ablation therapies (10.6%). The overall rate of adherence to the BCLC 
treatment guideline was only 37.7%. The 1-, 3-, and 5-year OS rates were 65.6%, 46.2%, and 
36.8%, respectively.
Conclusions: Between 2008 and 2011, approximately half of patients with HCC (48.3%) were 
candidates for curative treatment (BCLC stage 0 or A), but one-third of patients (33.8%) had 
advanced HCC (BCLC stage C). Transarterial therapy was the most commonly conducted initial 
treatment and the 5-year OS rate was 36.8% in this period. (J Liver Cancer 2020;20:41-52)
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cancers in Korea.1-3 Hepatocellular carcinoma (HCC) ac-
counts for more than 80-90% of primary liver cancer cases.4,5 
Korea is a hepatitis B virus (HBV)-endemic area, and chronic 
hepatitis B accounts for 62-75% of HCC etiology.6-8 As the 
prevalence of chronic hepatitis B increases with age, the inci-
dence and mortality rates of HCC are highest among the ec-
onomically active working-age (40-59 years) group.9 There-
fore, HCC imposes the highest economic burden among all 
cancers in Korea.10 To reduce the development of HCC and 
improve the prognosis of patients with HCC, a large number 
of studies regarding the management of HCC are published 
every year in Korea. Accurate information on the character-
istics and overall survival (OS) of patients with HCC is es-
sential to establish an optimal strategy for managing HCC. 
However, there has been a lack of large-scale, nationwide 
data to represent the typical characteristics of Korean patients 
with HCC. Therefore, we aimed to describe the baseline 
characteristics, treatment modalities, and OS of patients 
newly diagnosed with HCC utilizing a nationwide popula-
tion-based cancer registry in Korea. 
METHODS
1. Study population
The study population was selected from the patients regis-
tered in the Korean Primary Liver Cancer Registry (KPLCR). 
The KPLCR is a random sample consisting of approximately 
15% of patients newly diagnosed with primary liver cancer 
registered in the Korean Central Cancer Registry (KCCR), 
which is a nationwide cancer registry and includes more than 
95% of all cancer cases in Korea. The patients in the KPLCR 
were selected from the KCCR using a probability propor-
tional to size method and stratification by region in a given 
year. Therefore, the KPLCR is a representative group of pa-
tients with newly diagnosed HCC in Korea. We investigated 
the patients registered in the KPLCR between 2008 and 2011. 
All patients included in the study were diagnosed with HCC 
histologically or radiologically.11,12 We also performed surviv-
al analyses among patients who underwent the initial treat-
ment within 120 days from their diagnosis or received best 
supportive care (designated as the treatment group). Because 
the median doubling time of an HCC lesion is approximately 
117 days,13 patients who received the initial treatment more 
than 120 days after their diagnosis date were likely to receive 
the treatment at a more advanced tumor stage than their ini-
tial tumor stage. Therefore, we excluded patients who re-
ceived treatment more than 120 days after the initial date of 
diagnosis in the survival analyses. Because the KPLCR data 
in our study were collected as part of the KCCR in accor-
dance with the Cancer Control Act, the need for institutional 
review board approval was waived.
2. Basic statistics
Individual information about the study population was 
obtained from medical records at the hospital where the di-
agnosis was made. KCCR-trained registry recorders in each 
hospital investigated the medical records. Data were extract-
ed using a standardized case record form and validated by 
statisticians at the KCCR and the KPLCR. Collected data in-
cluded not only baseline characteristics such as demographic, 
laboratory, and tumor variables, but also treatment modali-
ties and OS of the patients. All of the tumor variables were 
assessed by diagnostic imaging such as dynamic computed 
tomography (CT) or magnetic resonance imaging (MRI). 
Both the modified Union for International Cancer Control 
(mUICC) staging system14,15 and the Barcelona Clinic Liver 
Cancer (BCLC) staging system16 were adapted as staging sys-
tems for HCC. 
3. Overall survival
The OS was measured from the date of the HCC diagnosis 
until death from any cause. The date of the HCC diagnosis 
was defined as the date when the patient underwent dynamic 
CT or MRI for the HCC diagnosis. Death certificate data 
were obtained from national statistical data collected by the 
Korean Ministry of Government Administration and Home 
Affairs. Individual data of patients' vital statistics were identi-
fied using 13-digit unique resident registration numbers is-
sued to all Koreans. Final data cut-off date was December 31, 
43
 Jun Sik Yoon, et al.
HCC in Korea: 2008-2011
https://www.e-jlc.org/
2017. The OS rates were obtained from the patients with 
HCC classified according to their baseline characteristics. 
The survival curves were also constructed according to the 
subgroups classified by the underlying liver functions and tu-
mor stages using the Kaplan-Meier method. The survival dif-
ferences were compared by the log-rank test. The survival 
analyses were conducted using R version 3.5.2 (http://www.
r-project.org) with P<0.05 considered statistically significant. 
RESULTS
1. Study population
Between 2008 and 2011, 6,146 patients were registered in 
the KPLCR. Of these, 63 patients were histologically diag-
nosed with other malignancies and excluded from the study. 
Therefore, 6,083 patients were selected as the study popula-
tion. Among the patients with HCC, we excluded 1) patients 
who received their initial treatment more than 120 days from 
the date of diagnosis (n=103) and 2) patients lacking infor-
mation on treatment modalities (n=6). As a result, 5,974 pa-
tients were selected as the treatment group. The treatment 
group consisted of patients who received active treatment 
(n=4,679) and those who received best supportive care 
(n=1,295). The flow diagram of the study population is 
shown in Supplementary Fig. 1.
2. Basic statistics
1) Baseline characteristics
The baseline characteristics of the study population 
(n=6,083) are presented in Table 1. The median age of the 
study population was 59 years (range, 2-98 years), and the 
majority were male (78.7%). HBV was the predominant eti-
ology (72.0%), followed by alcohol (13.4%), hepatitis C virus 
(12.0%), and others (2.5%). When the underlying liver func-
tion was estimated according to Child-Turcotte-Pugh (CTP) 
class, 71.0%, 23.7%, and 5.1% of patients were in CTP class-
es A, B, and C, respectively. According to the mUICC staging 
system, stage II (37.5%) was the most common, followed by 
stage III (26.1%), stage I (14.1%), stage IV-A (12.3%), and 
stage IV-B (9.9%). According to the BCLC staging system, 
stage A (39.7%) was the most common, followed by stage C 
(33.8%), stage B (11.5%), stage 0 (8.6%), and stage D 
(6.9%). A solitary tumor was observed in 61.5% of the pa-
tients, and the median maximal diameter of tumors was 3.0 
cm. Vascular invasions to the portal vein and hepatic vein 
were observed in 24.3% and 5.6% of the patients, respective-
ly. Lymph node metastasis and distant metastasis were ob-
served in 7.1% and 9.9% of patients, respectively.
2) Initial treatment modality
As shown in Table 2, of the patients in the treatment group 
(n=5,974), 17.6% underwent surgical therapies (i.e., surgical re-
section and liver transplantation), 54.2% underwent locore-
gional therapies (i.e., local ablation therapy, transarterial thera-
py, and a combination of local ablation and transarterial 
therapy), 3.7% underwent systemic therapy, 1.0% underwent 
external beam radiation therapy, 21.7% underwent best sup-
portive care, and 1.7% underwent miscellaneous therapies (i.e., 
combination therapies other than transarterial therapy and local 
ablation therapy). Transarterial therapy (41.7%) was the most 
commonly performed therapy or procedure as an initial treat-
ment, followed by best supportive care (21.7%), surgical resec-
tion (16.7%), and local ablation therapies (10.6%). The majority 
of local ablation therapies was radiofrequency ablation (594/636, 
99.4%). Among the transarterial therapies, conventional trans-
arterial chemoembolization with or without a gelatin sponge 
was the most frequently performed procedure (2,407/2,493, 
96.6%). Sorafenib was the most commonly used agent for sys-
temic therapy (175/224, 78.1%).
The treatment modalities used at each BCLC stage are pre-
sented in Fig. 1. For BCLC stage 0 or A, transarterial therapy 
(41.8%) was the most commonly conducted initial treat-
ment, followed by surgical therapy (27.3%) and local abla-
tion therapy (19.4%). , and it was for BCLC stages B and C 
as well. BCLC stages B and C. Although systemic therapy is a 
standard treatment modality of BCLC stage C, it was con-
ducted in only 9.5% of patients with BCLC stage C. For 
BCLC stage D, best supportive care was the most commonly 
conducted treatment modality. We show the rates of adher-
ence to the BCLC treatment guideline according to each 
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BCLC stage in Supplementary Table 1. The overall adherence 
rate of the total study population was only 37.4%. We also 
show the treatment modalities according to each mUICC 
stage in Supplementary Fig. 2. Transarterial therapy was the 
most commonly conducted initial treatment for mUICC 
stages I-III. For mUICC stage IV, best supportive care was 
the most commonly conducted treatment modality. 
3)  Baseline characteristics according to treatment mo-
dalities
The baseline characteristics of the patients treated with 
surgical therapies including surgical resection (n=998) and 
liver transplantation (n=55) are presented in Supplementary 
Table 2. Most patients treated with surgical resection had a 
good performance status of 0 or 1 (99.4%) and well-pre-
served liver function of CTP class A (95.4%). Of the patients 
treated with surgical resection, 21.2%, 53.6%, and 25.2% had 
a maximal tumor diameter measuring ≤2, 2-5, and ≥5 cm, 
respectively; 85.9% of these tumors were solitary. In the case 
of liver transplantation, more than half of the patients had 
poor liver function of CTP class B or C (53.8%) and multiple 
tumors (50.9%).
The baseline characteristics of the patients treated with lo-
coregional therapies including local ablation therapy 
(n=636), transarterial therapy (n=2,493), and a combination 
of local ablation and transarterial therapy (n=108) are pre-
sented in Supplementary Table 3. Most patients had a good 
performance status of 0 or 1 (98.0%, 96.4%, and 98.8% of 
patients treated with local ablation therapy, transarterial 
therapy, and combination therapy, respectively) and well-
preserved liver function classified as CTP class A (80.8 %, 
75.1%, and 78.8% of patients treated with local ablation 
therapy, transarterial therapy, and combination therapy, re-
spectively). The proportion of patients with multiple tumors 
and the median maximal diameter of tumors were highest in 
patients treated with transarterial therapy (43.1% and 3.0 
cm), followed by combination therapy (32.7% and 2.0 cm) 
and local ablation therapy (15.6% and 1.9 cm).
The baseline characteristics of the patients treated with 
other therapies, including systemic therapy (n=224), external 
beam radiation therapy (n=61), best supportive care 
Table 1. Baseline characteristics of the study population (n = 6,083)
Variable Value
Demographic variable
Age (years) 59.0 (51.0-68.0)
Sex (male) 4,790 (78.7)
Diabetes 1,401 (23.0)
Hypertension 1,808 (29.7)
Body mass index (kg/m2) 23.7 (21.7-25.8)
Smoking 2,657 (43.7)












Ascites (n=6,006, missing values=77)
None 4,509 (75.1)
Mild 964 (16.1)
Moderate to severe 533 (8.9)
Encephalopathy (n=6,045, missing 
values=38)
None 5,894 (97.5)
Mild to moderate (grade 1 or 2) 119 (2.0)
Severe (grade 3 or 4) 32 (0.5)
Laboratory variables
Total bilirubin (mg/dL) 1.0 (0.70-1.60)
Serum albumin (g/dL) 3.8 (3.2-4.2)
Alanine aminotransferase (IU/L) 38.0 (24.0-61.0)
Platelet count (109/L) 139.0 (95.0-199.0)
Prothrombin time (INR) 1.11 (1.04-1.22)
Creatinine (mg/dL) 0.90 (0.74-1.00)
Sodium (mmol/L) 139.0 (136.0-141.0)
Glucose (mg/dL) 109.0 (94.0-139.0)
Total cholesterol (mg/dL) 155.0 (130.0-182.0)
Alpha-fetoprotein (ng/mL) 47.4 (7.3-785.0)
PIVKA-II (mAU/mL) 144.5 (30.0-1,373.0)
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(n=1,295), and miscellaneous therapies (n=104), are pre-
sented in Supplementary Table 4. The proportions of pa-
tients with a poor performance status (≥2) and poor liver 
function (CTP class B or C) were the highest in patients 
treated with best supportive care (23.6% and 58.0%), fol-
lowed by external beam radiation therapy (13.2% and 
53.4%) and systemic therapy (7.9% and 39.2%). The pro-
portion of patients with multiple tumors and the median 
maximal diameter of tumors were highest in patients treated 
with systemic therapy (67.0% and 7.0 cm), followed by best 
supportive care (59.1% and 6.0 cm) and external beam radia-
tion therapy (47.5% and 4.2 cm).
Variable Value





MELD score 8.6 (7.3-11.1)
MELD-Na score 10.1 (8.0-13.8)
Tumor variable







Maximal tumor diameter (cm) 3.0 (2.0-5.4)
Portal vein invasion 1,477 (24.3)
Hepatic vein invasion 339 (5.6)
Bile duct invasion 159 (2.6)
Lymph node metastasis 431 (7.1)
Distant metastasis 602 (9.9)
Modified UICC stage (n=6,045, missing 
values=38)
Stage I 854 (14.1)
Stage II 2,267 (37.5)
Stage III 1,577 (26.1)
Stage IV-A 746 (12.3)
Stage IV-B 601 (9.9)






Values are presented as median (interquartile range) or number (%). 
HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international 
normalized ratio; PIVKA-II, protein induced by vitamin K absence-II; 
MELD, model for end-stage liver disease; UICC, Union for International 
Cancer Control; BCLC, Barcelona Clinic Liver Cancer. 
*Patients co-infected with HBV and HCV (n=87) were also included; 
†Performance status was defined as follows: 0, fully active without 
symptoms; 1, ambulatory with symptoms; 2, bedridden <50% of 
the time; 3, bedridden >50% of the time but capable of self-care; 4, 
bedridden 100% of the time and incapable of self-care.
Table 1. Continued Table 2. The initial treatment modality of the patients in the 
treatment group (n = 5,974)
Treatment modality Value
Surgical resection 998 (16.7)
Liver transplantation 55 (0.9)
Local ablation therapy 636 (10.6)
RFA 594
PEI 37
Other local ablation 5
Transarterial therapy 2,493 (41.7)
Conventional TACE 2,407
TACE with drug-eluting beads 64
Radioembolization 7
HAIC 82
Combination therapy* 108 (1.8)
Systemic therapy 224 (3.7)
Sorafenib 175
Other systemic agents 77
External beam radiation therapy 61 (1.0)
Best supportive care 1,295 (21.7)
Miscellaneous therapies† 104 (1.7)
Values are presented as number (%) unless otherwise indicated.
RFA, radiofrequency ablation; PEI, percutaneous ethanol injection; 
TACE, transarterial chemoembolization; HAIC, hepatic arterial 
infusional chemotherapy.
*Combination therapy is defined as the combined treatment of local 
ablation therapy and transarterial therapy; †Miscellaneous therapies 
are defined as unclassifiable treatment modalities (i.e., combination 
therapies other than transarterial therapy and local ablation therapy).
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3. Overall survival
The OS rates of the patients in the HCC group classified 
according to their baseline characteristics and their initial 
treatment modalities are presented in Table 3. The 1-, 3-, 
and 5-year OS rates for the entire study population were 
65.6%, 46.2%, and 36.8%, respectively (Fig. 2A). All of the 
variables included in the formula of the CTP class (presence 
of ascites and hepatic encephalopathy, the serum levels of 
bilirubin and albumin, and prothrombin time) showed a 
good discriminatory performance on the prognosis of pa-
tients with HCC (all log-rank P<0.001; Supplementary Fig. 3). 
All of the survival curves according to CTP class (Fig. 2B), 
mUICC stage (Fig. 2C), and BLCL stage (Fig. 2D) showed 
significant survival differences (all log-rank P <0.001). We 
also performed post hoc analyses of log-rank tests for multi-
ple comparisons between each survival curve. We found sig-
nificant survival differences among all CTP classes and all 
vHCC stages (all pairwise comparisons of log-rank P<0.001).
Figure 1. The initial treatment modality of the study population (A) and subgroups according to the Barcelona Clinic Liver Cancer (BCLC) stage 0 
(B), stage A (C), stage B (D), stage C (E), and stage D (F). *Combination therapy is defined as the combined treatment of local ablation therapy and 
transarterial therapy; †Miscellaneous therapies are defined as unclassifiable treatment modalities (i.e., combination therapies other than 
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Table 3. Overall survival rates (%) of the study population according to the baseline characteristics and the initial treatment modalities
Variable Value
Year
1 2 3 4 5
All case 6,083 (100) 65.6 54.3 46.2 40.9 36.8 
Age (years, n=6,078, missing values=5)  
<40 187 (3.1) 59.9 50.8 43.9 40.6 40.1 
40-49 982 (16.2) 61.7 51.8 44.8 40.4 38.7 
50-59 1,955 (32.2) 68.1 57.7 50.3 45.6 41.5 
60-69 1,696 (27.9) 68.6 57.3 49.1 43.6 39.1 
≥70 1,258 (20.77) 61.8 47.4 37.5 30.4 24.3 
Sex (n=6,083, missing values=0)  
Male 4,790 (78.7) 64.6 53.3 45.0 39.8 35.8 
Female 1,293 (21.3) 69.5 57.9 50.8 45.1 40.4 
Ascites (n=6,006, missing values=77)  
None 4,509 (75.1) 76.2 64.4 55.8 49.9 45.1 
Mild 964 (16.1) 37.9 27.4 21.1 17.1 14.3 
Moderate to severe 533 (8.9) 26.6 18.6 12.2 9.9 9.0 
Encephalopathy (n=6,045, missing values=38)  
None 5,894 (97.5) 66.5 55.1 47.0 41.7 37.5 
Mild to moderate (grade 1 or 2) 119 (2.0) 37.8 28.6 20.2 13.4 11.8 
Severe (grade 3 or 4) 32 (0.5) 28.1 28.1 18.8 18.8 18.8 
Serum albumin (g/dL, n=5,871, missing values=212)  
<2.8 524 (8.9) 35.7 25.2 19.3 17.0 15.1 
2.8-3.5 1,730 (29.5) 53.0 40.9 32.1 25.8 21.3 
>3.5 3,617 (61.6) 76.6 65.6 57.5 52.0 47.7 
Serum bilirubin (mg/dL, n=5,900, missing values=83)  
<2.0 4,842 (82.1) 72.0 60.3 51.4 45.9 41.4 
2.0-3.0 522 (8.8) 48.1 36.8 30.1 23.9 20.7 
>3.0 536 (9.1) 28.4 21.5 18.5 15.1 13.6 
Prothrombin time (INR, n=5,733, missing values=350)  
<1.7 5,599 (97.7) 66.8 55.5 47.3 41.8 37.5 
1.7-2.3 99 (1.7) 38.4 28.3 24.2 20.2 17.2 
>2.3 35 (0.6) 20.0 20.0 17.1 14.3 14.3 
Child-Turcotte-Pugh classification (n=5,719, missing values=375)  
A 4,063 (71.2) 77.3 66.0 57.0 51.1 46.4 
B 1,354 (23.7) 42.2 30.4 23.5 19.0 15.6 
C 291 (5.1) 20.6 15.1 11.0 8.9 8.6 
Tumor number (n=6,061, missing values=22)
1 3,725 (61.5) 75.6 65.4 57.1 51.7 47.0 
2 826 (13.6) 75.3 59.8 49.2 41.4 36.8 
3 247 (4.1) 74.5 55.5 42.1 32.0 25.1 
4 95 (1.6) 55.8 41.1 32.6 25.3 21.1 
≥5 1,168 (19.3) 26.1 15.8 11.3 9.2 7.8 
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1 2 3 4 5
Maximal tumor diameter (cm, n=6,040, missing values=43)  
<2 1,185 (19.6) 90.0 81.5 72.7 66.3 59.7 
2-4.9 2,346 (38.8) 83.4 71.9 61.8 54.4 48.8 
5-9.9 1,180 (19.5) 52.3 37.2 28.7 24.1 22.1 
≥10 1329 (22.0) 24.6 14.4 10.8 9.6 8.1 
Portal vein invasion (n=6,083, missing values=0)  
None 4,606 (75.7) 79.1 67.5 57.9 51.5 46.4 
Yes 1,477 (24.3) 23.6 13.1 9.6 7.9 6.7 
Hepatic vein invasion (n=6,083, missing values=0)  
None 5,744 (94.4) 68.1 56.7 48.4 42.8 38.5 
Yes 329 (5.6) 24.5 13.3 8.6 8.6 8.0 
Bile duct invasion (n=6,083, missing values=0)  
None 5,924 (97.4) 66.5 55.1 46.9 41.5 37.4 
Yes 159 (2.6) 34.0 23.9 19.5 18.2 15.1 
T classification (n=6,041, missing values=42)  
T1 860 (14.2) 93.3 86.6 78.0 72.3 65.5 
T2 2,396 (39.7) 84.0 73.0 63.4 56.8 51.7 
T3 1,954 (32.3) 51.1 36.3 28.1 22.7 19.4 
T4 831 (13.8) 18.7 9.7 6.4 5.7 4.8 
N classification (n=6,083, missing values=0)  
N0 5,652 (92.9) 69.2 57.6 49.1 43.5 39.1 
N1 431 (7.1) 19.0 10.9 8.1 7.0 6.0 
M classification (n=6,083, missing values=0)  
M0 5,481 (90.1) 71.1 59.3 50.7 44.9 40.4 
M1 602 (9.9) 16.1 8.6 5.3 4.8 4.0 
Distant metastasis sites (n=569, missing values=33)  
Bone 93 (16.3) 14.0 3.2 2.2 1.1 1.1 
Lung 260 (45.7) 16.2 8.1 5.0 4.6 3.5 
Distant lymph node 64 (11.2) 15.6 7.8 6.2 4.7 4.7 
Lung and bone 31 (5.4) 6.5 3.2 0.0 0.0 0.0 
Bone and distant lymph node 11 (1.9) 36.4 9.1 9.1 9.1 9.1 
Lung and distant lymph node 29 (5.1) 3.4 3.0 0.0 0.0 0.0 
Bone and lung and distant lymph node 9 (1.6) 11.1 0.0 0.0 0.0 0.0 
Others 72 (12.7) 16.7 12.5 8.3 8.3 6.9 
Modified UICC stage (n=6,045, missing values=38)  
Stage I 854 (14.1) 93.4 86.8 78.2 72.6 65.7 
Stage II 2,267 (37.5) 86.5 75.7 66.1 59.2 54.0 
Stage III 1,577 (26.1) 59.0 42.8 33.4 26.9 23.1 
Stage IV-A 746 (12.3) 24.5 13.4 9.2 7.8 6.6 
Stage IV-B 601 (9.9) 16.0 8.5 5.3 4.8 4.0 
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DISCUSSION
The aim of this study was to investigate the baseline char-
acteristics, treatment modalities, and OS of patients with 
newly diagnosed HCC in Korea. We analyzed 6,083 patients 
with HCC registered in the KPLCR, which is a representative 
group of patients with newly diagnosed HCC in Korea, be-
tween 2008 and 2011. We found that approximately half of 
the patients with HCC (48.3%) were candidates for curative 
treatment (BCLC stage 0 or A), but one-third of patients 
(33.8%) had advanced HCC (BCLC stage C). Transarterial 
therapy (41.7%) was the most commonly conducted initial 
treatment, followed by best supportive care (21.7%), surgical 
resection (16.7%), and local ablation therapy (10.6%). The 
1-, 3-, and 5-year OS rates were 65.6%, 46.2%, and 36.8%, 
respectively.
The nationwide surveillance program for HCC in a high-
risk population (i.e., patients over 40 years of age who had 
chronic hepatitis B, chronic hepatitis C, or liver cirrhosis) 
was started in 2003 in Korea. As a result, early detection of 
HCC has gradually been increasing over time. We compared 
the results of this study (KPLCR data between 2008 and 
2011) with the KPLCR data between 2003 and 2005 (data ex-
tracted from http://www.livercancer.or.kr). The proportion 
of patients with mUICC stage I increased from 10.7% in the 
2003-2005 period to 14.1% in the 2008-2011 period. More-
over, 64.2%, 27.0%, and 8.8% of patients in the 2003-2005 
period were in CTP class A, B, and C, respectively, whereas 
71.0%, 23.8%, and 5.1% of patients in the 2008-2011 period 
were in CTP class A, B, and C, respectively. These data indi-
cate that the detection of patients with early TNM-stage 
HCC with well-preserved liver function has been increasing 
over time. Therefore, the 1-, 3-, and 5-year OS rates also in-
creased from 54.8%, 35.0%, and 26.4% in the 2003-2005 pe-





1 2 3 4 5
BCLC stage (n=5,697, missing values=386)  
0 489 (8.6) 97.5 93.5 87.7 81.2 74.0 
A 2,259 (39.7) 89.2 78.4 68.5 61.5 56.0 
B 657 (11.5) 72.3 54.2 41.1 32.4 27.4 
C 1,919 (33.7) 37.9 25.8 19.6 17.0 14.6 
D 373 (6.5) 18.8 13.4 9.4 7.8 7.5 
Initial treatment modalities (n=5,974, missing values=109)  
Surgical resection 998 (17.6) 93.1 88.0 81.4 77.5 74.4 
Liver transplantation 55 (0.9) 89.1 83.6 80.0 78.2 78.2 
Local ablation therapy 636 (10.6) 94.2 86.5 78.0 71.4 65.1 
Transarterial therapy 2,493 (41.7) 72.8 57.0 45.4 37.8 32.0 
Combination therapy* 108 (1.8) 94.4 84.3 79.6 72.2 65.7 
Systemic therapy 224 (3.7) 18.8 9.4 6.2 5.8 4.5 
External beam radiation therapy 61 (1.0) 24.6 13.1 8.2 6.6 4.9 
Best supportive care 1,295 (21.7) 25.6 17.2 14.1 11.9 10.0 
Miscellaneous therapies† 104 (1.7) 45.2 23.1 12.5 8.7 5.8 
Values are expressed as median (interquartile range) or number (%).
INR, international normalized ratio; UICC, Union for International Cancer Control; BCLC, Barcelona Clinic Liver Cancer.
*Combination therapy is defined as the combined treatment of local ablation therapy and transarterial therapy; †Miscellaneous therapies are 
defined as unclassifiable treatment modalities (i.e., combination therapies other than transarterial therapy and local ablation therapy).
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Approximately half of the patients with HCC (48.3%) 
were candidates for curative treatment (BCLC stage 0 or A) 
in this study. The detection rate of BCLC stage 0 or A was 
higher than that in Western countries (approximately 30%), 
where nationwide surveillance programs are yet to be imple-
mented.17,18 However, the detection rate was lower than that 
in Japan (62.5%) where a nationwide surveillance program 
began in 1980.19 Probably owing to this reason, the 5-year 
survival rate of Korean patients with HCC in this study 
(36.8%) was higher than that in Western countries (9.6-
18.0%),20-22 but lower than that in Japan (50.8%) during a 
similar study period.23 The reason patients with HCC in Ko-
rea had a lower 5-year survival rate than patients in Japan is 
not only because of the low detection rate of BCLC stage 0 or 
A (48.3% vs. 62.5%), but also because of the high detection 
rate of BCLC stage C or D (40.6% vs. 6.0%).19 Intensive sur-
veillance for detecting HCC at earlier stages might be re-
quired to improve the survival of patients with HCC in Ko-
rea.
In the present study, the most commonly conducted initial 
treatment was transarterial therapy (41.7%), followed by best 
supportive care (21.7%), surgical resection (16.7%), and lo-
cal ablation therapy (10.6%). Transarterial therapy was the 
most commonly performed treatment for all HCC stages ex-
cept mUICC stage IV or BCLC stage D, which was consistent 
with results in Western countries.17 However, the overall rate 
of adherence to BCLC treatment guidelines was only 37.4%, 
which was lower than that of Western countries (58.1-
70.6%).24-26 In particular, the adherence rates of BCLC stage 
0 or A and BCLC stage C were as low as 47.4% and 9.5%, re-
spectively. Liver transplantation, one of the standard treat-
ment modalities for BCLC stage 0 or A, was performed in 
Figure 2. Overall survival curves for the study population (A) and subgroups divided by the Child-Turcotte-Pugh classes (B) and the modified 
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only 0.7% of the patients with BCLC stage 0 or A stage. 
Moreover, approximately half of the patients in BCLC stage 
C underwent other therapies rather than the recommended 
systemic therapy; 39.8%, 8.1%, and 2.4% were treated with 
transarterial therapy, surgical resection, and local ablation 
therapy, respectively. The discrepancies of the real-world 
treatment from the recommended treatment are thought to 
be caused by an extreme shortage of liver donors and the low 
anticipated survival benefit of systemic therapy.
In conclusion, we have shown that, between 2008 and 
2011, approximately half of Korean patients newly diagnosed 
with HCC had BCLC stage 0 or A, but one-third of the pa-
tients had BCLC stage C. Transarterial therapy was the most 
commonly conducted initial treatment, and the 5-year OS 
was 36.8% in this period. We believe that the results de-
scribed here will contribute to the clinical management of 
HCC and promote future study.
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Supplementary Table 1. Adherence rates of the BCLC treatment 
guideline in each Barcelona Clinic Liver Cancer stage and total study 
population
BCLC stage Value





Values are presented as number (%).
BCLC, Barcelona Clinic Liver Cancer.
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Supplementary Table 2. Baseline characteristics of the patients treated with surgical therapies (n=1,053)
Variable Surgical resection (n=998, 16.7%) Liver transplantation (n=55, 0.9%)
Demographic variable
  Age (years) 56.0 (49.0-64.0) 52.0 (47.0-58.5)
  Sex (male) 792 (79.4) 45 (81.8)
  Diabetes 196 (19.6) 8 (14.5)
  Hypertension 312 (31.7) 5 (9.3)
  Body mass index (kg/m2) 23.7 (21.9-25.8) 24.8 (22.4-27.4)
  Smoking 428 (43.4) 25 (46.3)
  Etiology n=879 n=52
    HBV* 710 (80.8) 46 (88.5)
    HCV 64 (7.3) 4 (7.7)
    Alcohol 87 (9.9) 2 (3.8)
    Others 18 (2.0) 0
  Performance status† n=782 n=41
    0 705 (90.2) 30 (73.2)
    1 72 (9.2) 6 (14.6)
    2 4 (0.5) 3 (7.3)
    3 1 (0.1) 0 
    4 0 2 (4.9)
  Ascites n=998 n=55
    None 957 (95.9) 37 (67.3)
    Mild 37 (3.7) 9 (16.4)
    Moderate to severe 4 (0.4) 9 (16.4)
  Encephalopathy n=991 n=55
    None 988 (99.7) 51 (92.7)
    Mild to moderate (grade 1 or 2) 2 (0.2) 4 (7.3)
    Severe (grade 3 or 4) 1 (0.1) 0 
Laboratory variable
  Total bilirubin (mg/dL) 0.8 (0.6-1.0) 1.5 (0.9-2.9)
  Serum albumin (g/dL) 4.2 (3.8-4.4) 3.1 (2.8-3.6)
  Alanine aminotransferase (IU/L) 33.0 (22.0-48.0) 33.0 (26.0-42.0)
  Platelet count (109/L) 163.0 (124.0-208.0) 74.0 (53.0-112.0)
  Prothrombin time (INR) 1.05 (1.00-1.11) 1.31 (1.15-1.54)
  Creatinine (mg/dL) 0.90 (0.80-1.00) 0.90 (0.76-1.00)
  Sodium (mmol/L) 140.0 (138.0-142.0) 138.0 (135.0-140.5)
  Glucose (mg/dL) 105.0 (93.5-127.0) 104.0 (90.0-133.5)
  Total Cholesterol (mg/dL) 164.0 (142.0-185.0) 140.0 (116.0-159.0)
  Alpha-fetoprotein (ng/mL) 28.3 (5.4-304.3) 17.2 (6.5-106.4)
  PIVKA-II (mAU/mL) 79.5 (29.0-500.0) 31.5 (16.0-194.0)
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Variable Surgical resection (n=998, 16.7%) Liver transplantation (n=55, 0.9%)
  Child-Turcotte-Pugh class n=963 n=52
    A 919 (95.4) 24 (46.2)
    B 43 (4.5) 20 (38.5)
    C 1 (0.1) 8 (15.4)
  MELD score 7.4 (6.8-8.6) 11.2 (8.4-15.4)
  MELD-Na score 8.1 (7.1-9.8) 14.1 (9.6-19.2)
Tumor variable
  Tumor number n=988 n=53
    1 849 (85.9) 26 (49.1)
    2 112 (11.3) 11 (20.8)
    3 13 (1.3) 4 (7.5)
    4 3 (0.3) 1 (1.9)
    ≥5 11 (1.1) 11 (20.8)
  Maximal tumor diameter (cm) 3.2 (2.2-5.0) 2.5 (1.5-4.0)
  Portal vein invasion 60 (6.0) 7 (12.7)
  Hepatic vein invasion 14 (1.4) 0 
  Bile duct invasion 14 (1.4) 0 
  Lymph node metastasis 14 (1.4) 0 
  Distant metastasis 14 (1.4) 0 
  Modified UICC stage n=988 n=53
    Stage I 120 (12.1) 6 (11.3)
    Stage II 674 (68.2) 23 (43.4)
    Stage III 155 (15.7) 22 (41.5)
    Stage IV-A 25 (2.5) 2 (3.8)
    Stage IV-B 14 (1.4) 0 
  BCLC stage n=956 n=51
    0 89 (9.3) 2 (3.9)
    A 646 (67.6) 17 (33.3)
    B 66 (6.9) 13 (25.5)
    C 153 (16.0) 10 (19.6)
    D 2 (0.2) 9 (17.6)
Values are expressed as median (interquartile range) or number (%).
HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; PIVKA-II, protein induced by vitamin K absence-II; MELD, Model 
for End Stage Liver Disease; UICC, Union for International Cancer Control; BCLC, Barcelona Clinic Liver Cancer.
*Patients co-infected with HBV and HCV were also included; †Performance status was defined as follows: 0, fully active without symptoms; 1, 
ambulatory with symptoms; 2, bedridden <50% of the time; 3, bedridden >50% of the time but capable of self-care; 4, bedridden 100% of the 
time and incapable of self-care.
Supplementary Table 2. Continued
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Supplementary Table 3. Baseline characteristics of the patients treated with locoregional therapies (n=3,237)
Variable







  Age (years) 60.0 (52.0-68.0) 60.0 (52.0-68.0) 60.0 (52.5-67.0)
  Sex (male) 462 (72.6) 1,968 (78.9) 80 (74.1)
  Diabetes 161 (25.3) 621 (24.9) 34 (31.5)
  Hypertension 187 (29.6) 798 (32.4) 39 (36.1)
  Body mass index (kg/m2) 24.3 (22.2-26.2) 23.7 (21.8-26.0) 24.2 (22.4-26.7)
  Smoking 238 (37.7) 1,148 (46.4) 45 (41.7)
  Etiology n=574 n=2,207 n=86
    HBV† 387 (67.4) 1,558 (70.6) 65 (75.6)
    HCV 96 (16.7) 287 (13.0) 9 (10.5)
    Alcohol 71 (12.4) 302 (13.7) 10 (11.6)
    Others 20 (3.5) 60 (2.7) 2 (2.3)
  Performance status‡ n=418 n=1,728 n=81
    0 384 (91.9) 1,421 (82.2) 75 (92.6)
    1 26 (6.2) 245 (14.2) 5 (6.2)
    2 6 (1.4) 44 (2.5) 1 (1.2)
    3 2 (0.5) 11 (0.6) 0 
    4 0 7 (0.4) 0 
  Ascites n=636 n=2,493 n=108
    None 553 (86.9) 1,961 (78.7) 94 (87.0)
    Mild 58 (9.1) 364 (14.6) 13 (12.0)
    Moderate to severe 25 (3.9) 168 (6.7) 1 (0.9)
  Encephalopathy n=633 n=2,479 n=108
    None 624 (98.6) 2,435 (98.2) 107 (99.1)
    Mild to moderate (grade 1 or 2) 5 (0.8) 33 (1.3) 1 (0.9)
    Severe (grade 3 or 4) 4 (0.6) 11 (0.4) 0 
Laboratory variable
  Total bilirubin (mg/dL) 0.9 (0.7-1.4) 1.0 (0.7-1.5) 0.8 (0.5-1.3)
  Serum albumin (g/dL) 3.9 (3.4-4.2) 3.7 (3.3-4.1) 3.9 (3.4-4.2)
  Alanine aminotransferase (IU/L) 34.0 (22.0-52.0) 37.0 (24.0-58.0) 33.0 (22.0-48.5)
  Platelet count (109/L) 110.0 (75.5-152.0) 126.0 (86.0-185.0) 111.0 (77.0-134.5)
  Prothrombin time (INR) 1.12 (1.05-1.23) 1.11 (1.04-1.23) 1.12 (1.06-1.19)
  Creatinine (mg/dL) 0.90 (0.72-1.00) 0.90 (0.73-1.00) 0.90 (0.79-1.08)
  Sodium (mmol/L) 140.0 (138.0-142.0) 139.0 (137.0-141.0) 139.8 (138.0-142.0)
  Glucose (mg/dL) 108.0 (94.0-142.0) 110.0 (94.0-143.0) 116.0 (98.5-138.5)
  Total cholesterol (mg/dL) 155.5 (133.5-173.0) 152.0 (128.0-178.0) 149.0 (131.0-179.0)
  Alpha-fetoprotein (ng/mL) 12.3 (4.9-49.6) 43.3 (8.2-567.3) 12.1 (6.1-49.5)
  PIVKA-II (mAU/mL) 28.0 (18.5-56.5) 151.0 (29.5-1,200.0) 32.5 (16.0-89.0)
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Variable






  Child-Turcotte-Pugh class n=608 n=2,353 n=99
    A 491 (80.8) 1,767 (75.1) 78 (78.8)
    B 101 (16.6) 530 (22.5) 20 (20.2)
    C 16 (2.6) 56 (2.4) 1 (1.0)
  MELD score 8.6 (7.3-10.6) 8.6 (7.3-10.8) 8.5 (7.2-9.9)
  MELD-Na score 9.4 (7.7-12.2) 10.0 (8.1-13.1) 9.3 (7.7-11.5)
Tumor variable
  Tumor number n=636 n=2,490 n=107
    1 537 (84.4) 1,417 (56.9) 72 (67.3)
    2 81 (12.7) 409 (16.4) 23 (21.5)
    3 9 (1.4) 165 (6.6) 5 (4.7)
    4 0 60 (2.4) 1 (0.9)
    ≥5 9 (1.4) 439 (17.6) 6 (5.6)
  Maximal tumor diameter (cm) 1.9 (1.5-2.5) 3.0 (2.0-5.0) 2.0 (1.5-2.9)
  Portal vein invasion 15 (2.4) 483 (19.4) 14 (13.0)
  Hepatic vein invasion 1 (0.2) 98 (3.9) 2 (1.9)
  Bile duct invasion 0 48 (1.9) 0 
  Lymph node metastasis 5 (0.8) 127 (5.1) 2 (1.9)
  Distant metastasis 6 (0.9) 148 (5.9) 2 (1.9)
  Modified UICC stage n=633 n=2,484 n=107
    Stage I 281 (44.4) 326 (13.1) 32 (29.9)
    Stage II 280 (44.2) 937 (37.7) 45 (42.1)
    Stage III 62 (9.8) 787 (31.7) 21 (19.6)
    Stage IV-A 4 (0.6) 287 (11.6) 7 (6.5)
    Stage IV-B 6 (0.9) 147 (5.9) 2 (1.9)
  BCLC stage n=608 n=2,352 n=99
    0 169 (27.8) 186 (7.9) 19 (19.2)
    A 354 (58.2) 939 (39.9) 52 (52.5)
    B 22 (3.6) 406 (17.3) 9 (9.1)
    C 46 (7.6) 753 (32.0) 18 (18.2)
    D 17 (2.8) 68 (2.9) 1 (1.0)
Values are expressed as median (interquartile range) or number (%).
HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; PIVKA-II, protein induced by vitamin K absence-II; MELD, Model 
for End Stage Liver Disease; UICC, Union for International Cancer Control; BCLC, Barcelona Clinic Liver Cancer.
*Combination therapy is defined as the combined treatment of local ablation therapy and transarterial therapy; †Patients co-infected with HBV 
and HCV were also included; ‡Performance status was defined as follows: 0, fully active without symptoms; 1, ambulatory with symptoms; 2, 
bedridden <50% of the time; 3, bedridden >50% of the time but capable of self-care; 4, bedridden 100% of the time and incapable of self-care.
Supplementary Table 3. Continued
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Supplementary Table 4. Baseline characteristics of the patients treated with systemic therapy, external beam radiation therapy, best 




External beam radiation 
therapy (n=61, 1.1%)





  Age (years) 54.0 (47.5-64.0) 55.0 (47.0-64.0) 61.5 (52.5-71.0) 53.2 (48.0-57.0)
  Sex (male) 189 (84.4) 48 (78.7) 1,030 (79.5) 89 (85.6)
  Diabetes 35 (15.6) 8 (13.1) 302 (23.3) 11 (10.6)
  Hypertension 44 (19.8) 10 (17.2) 366 (29.9) 23 (22.1)
  Body mass index (kg/m2) 23.1 (21.3-24.9) 22.9 (20.9-25.4) 23.6 (21.5-26.1) 23.3 (21.2-25.0)
  Smoking 111 (50.2) 29 (48.3) 535 (43.7) 57 (54.8)
  Etiology n=205 n=55 n=1,037 n=99
    HBV† 158 (77.1) 47 (85.5) 694 (66.9) 84 (84.8)
    HCV 15 (7.3) 3 (5.5) 132 (12.7) 9 (9.1)
    Alcohol 22 (10.7) 5 (9.1) 192 (18.5) 4 (4.0)
    Others 10 (4.9) 0 19 (1.8) 2 (2.0)
  Performance status‡ n=164 n=38 n=772 n=80
    0 98 (59.8) 23 (60.5) 403 (52.2) 51 (63.8)
    1 53 (32.3) 10 (26.3) 187 (24.2) 25 (31.2)
    2 6 (3.7) 2 (5.3) 89 (11.5) 4 (5.0)
    3 2 (1.2) 2 (5.3) 53 (6.9) 0 
    4 5 (3.0) 1 (2.6) 40 (5.2) 0 
  Ascites n=224 n=61 n=1,295 n=104
    None 129 (57.6) 35 (57.4) 666 (51.4) 76 (73.1)
    Mild 63 (28.1) 20 (32.8) 357 (27.6) 25 (24.0)
    Moderate to severe 32 (14.3) 6 (9.8) 272 (21.0) 3 (2.9)
  Encephalopathy n=221 n=61 n=1,286 n=103
    None 213 (96.4) 57 (93.4) 1,218 (94.7) 102 (99.0)
    Mild to moderate (grade 1 or 2) 8 (3.6) 4 (6.6) 52 (4.0) 1 (1.0)
    Severe (grade 3 or 4) 0 0 16 (1.2) 0 
Laboratory variable
  Total bilirubin (mg/dL) 1.1 (0.8-1.7) 1.2 (0.8-1.9) 3.4 (0.8-3.3) 1.3 (0.6-1.2)
  Serum albumin (g/dL) 3.6 (3.2-4.0) 3.6 (3.0-3.9) 3.3 (2.8-3.7) 3.8 (3.4-4.2)
  Alanine aminotransferase (IU/L) 46.0 (30.0-75.0) 49.0 (34.0-83.0) 67.0 (24.5-85.0) 80.4 (22.0-78.6)
  Platelet count (109/L) 171.0 (123.0-244.0) 142.5 (112.0-204.0) 165.8 (86.5-218.0) 174.4 (104.0-221.0)
  Prothrombin time (INR) 1.12 (1.03-1.19) 1.15 (1.07-1.29) 1.23 (1.06-1.33) 1.10 (1.02-1.16)
  Creatinine (mg/dL) 0.90 (0.71-1.00) 0.80 (0.70-0.94) 0.97 (0.70-1.10) 0.80 (0.69-0.94)
  Sodium (mmol/L) 138.0 (135.0-140.0) 138.0 (134.0-140.0) 136.0 (134.0-140.0) 138.6 (137.0-140.0)
  Glucose (mg/dL) 106.5 (93.0-134.0) 116.0 (95.0-129.5) 143.3 (95.5-161.0) 114.4 (90.0-123.0)
  Total cholesterol (mg/dL) 164.5 (136.0-196.0) 165.0 (122.0-200.0) 156.1 (118.5-185.5) 163.4 (136.0-187.0)
  Alpha-fetoprotein (ng/mL) 1,750.0 (84.3-19,982.2) 726.0 (33.1-8,592.2) 11,658.3 (8.2-3,482.2) 12,250.7 (21.3-24,235.3)
  PIVKA-II (mAU/mL) 2,000.0 (818.0-2,000.0) 685.0 (88.5-2,000.0) 1,814.0 (83.5-2,000.0) 2,730.0 (292.0-2,000.0)
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External beam radiation 
therapy (n=61, 1.1%)




  Child-Turcotte-Pugh class n=212 n=58 n=1,169 n=98
    A 129 (60.8) 27 (46.6) 491 (37.9) 78 (79.6)
    B 75 (35.4) 30 (51.7) 485 (37.5) 19 (19.4)
    C 8 (3.8) 1 (1.7) 193 (14.9) 1 (1.0)
  MELD score 8.9 (7.5-10.9) 9.7 (7.8-11.3) 12.0 (8.2-14.5) 8.5 (7.0-9.8)
  MELD-Na score 11.3 (8.9-14.1) 12.4 (9.4-15.1) 14.4 (9.6-18.4) 9.8 (7.5-11.4)
Tumor variable
  Tumor number n=224 n=61 n=1,289 n=104
    1 74 (33.0) 32 (52.5) 598 (46.4) 50 (48.1)
    2 17 (7.6) 8 (13.1) 138 (10.7) 14 (13.5)
    3 8 (3.6) 0 30 (2.3) 7 (6.7)
    4 3 (1.3) 0 23 (1.8) 1 (1.0)
    ≥5 122 (54.5) 21 (34.4) 500 (38.8) 32 (30.8)
  Maximal tumor diameter (cm) 7.0 (4.8-10.0) 4.2 (2.5-8.0) 6.0 (2.9-9.0) 7.1 (4.6-8.8)
  Portal vein invasion 150 (67.0) 43 (70.5) 621 (48.0) 67 (64.4)
  Hepatic vein invasion 43 (19.2) 9 (14.8) 155 (12.0) 11 (10.6)
  Bile duct invasion 8 (3.6) 6 (9.8) 74 (5.7) 7 (6.7)
  Lymph node metastasis 49 (21.9) 16 (26.2) 192 (14.8) 17 (16.3)
  Distant metastasis 99 (44.2) 24 (39.3) 274 (21.2) 26 (25.0)
  Modified UICC stage n=224 n=61 n=1,284 n=103
    Stage I 1 (0.4) 1 (1.6) 56 (4.4) 3 (2.9)
    Stage II 11 (4.9) 4 (6.6) 243 (18.9) 11 (10.7)
    Stage III 41 (18.3) 14 (23.0) 418 (32.6) 34 (33.0)
    Stage IV-A 72 (32.1) 18 (29.5) 293 (22.8) 29 (28.2)
    Stage IV-B 99 (44.2) 24 (39.3) 274 (21.3) 26 (25.2)
  BCLC stage n=212 n=58 n=1,167 n=98
    0 0 0 15 (1.3) 1 (1.0)
    A 8 (3.8) 3 (5.2) 184 (15.8) 10 (10.2)
    B 10 (4.7) 1 (1.7) 116 (9.9) 4 (4.1)
    C 180 (84.9) 50 (86.2) 603 (51.7) 82 (83.7)
    D 14 (6.6) 4 (6.9) 249 (21.3) 1 (1.0)
Values are expressed as median (interquartile range) or number (%).
HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
PIVKA-II, protein induced by vitamin K absence-II; MELD, Model for End Stage Liver Disease; UICC, Union for International Cancer Control; BCLC, 
Barcelona Clinic Liver Cancer.
*Miscellaneous therapies are defined as unclassifiable treatment modalities (i.e., combination therapies other than transarterial therapy and local 
ablation therapy); †Patients co-infected with HBV and HCV were also included; ‡Performance status was defined as follows: 0, fully active without 
symptoms; 1, ambulatory with symptoms; 2, bedridden <50% of the time; 3, bedridden >50% of the time but capable of self-care; 4, bedridden 
100% of the time and incapable of self-care.
Supplementary Table 4. Continued
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Supplementary Fig. 1. Flow diagram of the study population. KPLCR, Korean Primary Liver Cancer Registry; HCC, hepatocellular carcinoma.
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Supplementary Fig. 2. The initial treatment modality of the study population according to the modified Union for International Cancer Control 
staging system. *Combination therapy is defined as the combined treatment of local ablation therapy and transarterial therapy; †Miscellaneous 
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Supplementary Fig. 3. Cumulative survival curves for the subgroups according to the presence of ascites (A) and hepatic encephalopathy (B), 
the serum levels of bilirubin (C) and albumin (D), and prolongation (seconds) of prothrombin time (E).
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